IN THE NEWS
Digital Journal, December 2017
Xconomy, February 2015
ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The company’s proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
Acelerox is investigating a proprietary class of therapeutics, termed PEG-HCCs, which were developed and produced in Dr. James Tour’s laboratory at Rice University. PEG-HCCs are superior to all known existing therapeutic antioxidants in that they:
> preferentially scavenge SO and hydroxyl radicals
> exhibit potent yet selective antioxidant activity
> do not react with nitric oxide (an important signaling molecule for normal cell function)
> do not pass radicals onto other molecules
> are bioavailable
> exhibit low toxicity in rodents
> do not rapidly inactivate
> do not require assistance from auxiliary molecules.
Due to the wide ranging effects of oxidative stress, the company’s proprietary compounds could be used in a wide range of diseases. Proof-of-concept data show that
administration of these novel materials reversed the symptoms of RA, reduced severity of stroke and TBI, and significantly reduces clinical signs of MS and AD in appropriate animal models.